- Home
- LIXT vs APVO Comparison
LIXT vs APVO Comparison
Compare LIXT & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- APVO
- Stock Information
- Founded
- LIXT 2005
- APVO 2016
- Country
- LIXT United States
- APVO United States
- Employees
- LIXT N/A
- APVO N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- APVO Health Care
- Exchange
- LIXT Nasdaq
- APVO Nasdaq
- Market Cap
- LIXT 12.4M
- APVO 4.1M
- IPO Year
- LIXT N/A
- APVO N/A
- Fundamental
- Price
- LIXT $3.41
- APVO $1.98
- Analyst Decision
- LIXT
- APVO Strong Buy
- Analyst Count
- LIXT 0
- APVO 1
- Target Price
- LIXT N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- LIXT 136.6K
- APVO 122.5K
- Earning Date
- LIXT 08-07-2025
- APVO 08-11-2025
- Dividend Yield
- LIXT N/A
- APVO N/A
- EPS Growth
- LIXT N/A
- APVO N/A
- EPS
- LIXT N/A
- APVO N/A
- Revenue
- LIXT N/A
- APVO N/A
- Revenue This Year
- LIXT N/A
- APVO N/A
- Revenue Next Year
- LIXT N/A
- APVO N/A
- P/E Ratio
- LIXT N/A
- APVO N/A
- Revenue Growth
- LIXT N/A
- APVO N/A
- 52 Week Low
- LIXT $0.64
- APVO $1.72
- 52 Week High
- LIXT $5.14
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- LIXT 44.33
- APVO 32.74
- Support Level
- LIXT $3.13
- APVO $1.87
- Resistance Level
- LIXT $4.04
- APVO $2.07
- Average True Range (ATR)
- LIXT 0.57
- APVO 0.18
- MACD
- LIXT -0.22
- APVO 0.04
- Stochastic Oscillator
- LIXT 16.66
- APVO 29.55
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.